Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

DSpace/Manakin Repository

Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review

Citable link to this page

 

 
Title: Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
Author: Schoenfeld, Jonathan D.; Mahadevan, Anand; Floyd, Scott R.; Dyer, Michael A.; Catalano, Paul J.; Alexander, Brian M.; McDermott, David F.; Kaplan, Irving D.

Note: Order does not necessarily reflect citation order of authors.

Citation: Schoenfeld, Jonathan D., Anand Mahadevan, Scott R. Floyd, Michael A. Dyer, Paul J. Catalano, Brian M. Alexander, David F. McDermott, and Irving D. Kaplan. 2015. “Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review.” Journal for Immunotherapy of Cancer 3 (1): 50. doi:10.1186/s40425-015-0095-8. http://dx.doi.org/10.1186/s40425-015-0095-8.
Full Text & Related Files:
Abstract: Background: Ipilimumab improves survival in metastatic melanoma patients. This population frequently develops brain metastases, which have been associated with poor survival and are often treated with radiation. Therefore, outcomes following ipilimumab and radiation are of interest, especially given case reports and animal studies suggest combined treatment may generate abscopal responses outside the radiation field. Findings: We reviewed sixteen consecutive melanoma patients who received 1 to 8 courses of radiation, with a sum total of 51, systematically evaluating abscopal responses by following the largest extra-cranial lesion. We also reviewed other series of patients treated with cranial radiation and ipilimumab. Our patients received between 1 and 8 courses of cranial radiation. Four patients received radiation concurrently with ipilimumab. Median survival was 14 months, and 17 months in patients initially treated with SRS. Interestingly, after radiotherapy, there was a 2.8-fold increased likelihood that the rate of extra-cranial index lesion response improved that didn’t reach statistical significance (p = 0.07); this was more pronounced when ipilimumab was administered within three months of radiation (p < 0.01). Conclusion: Our experience and review of recently published series suggest ipilimumab and cranial radiation is well tolerated and can result in prolonged survival. Timing of ipilimumab administration in relation to radiation may impact outcomes. Additionally, our results demonstrate a trend for favorable systemic response following radiotherapy worthy of further evaluation in studies powered to detect potential synergies between radiation and immunotherapy.
Published Version: doi:10.1186/s40425-015-0095-8
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678639/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:23993701
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters